Hoppa till innehåll
Home
About us
Team
Board of Directors
Our product
EMP16
Clinical Program
Publications
News & Media
Media
Press Releases
Blog
Contact
Home
About us
Team
Board of Directors
Our product
EMP16
Clinical Program
Publications
News & Media
Media
Press Releases
Blog
Contact
Press Releases
Home
Press Releases
Press releases
Empros Pharma Launches Pilot Trial Ahead of EMP16 Phase III Program
Press releases
Empros phase 2b obesity trial enrollment complete in only one month..
Press releases
Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16
Press releases
Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16
Press releases
Empros enters late stage clinical development of obesity treatment EMP16
Press releases
Empros and Megapharm announce letter of intent
Press releases
Securing 40 msek investment
Press releases
Results from phase IIA trial published in major scientific journal
Press releases
Annual general meeting
Press releases
Pharmacokinetics publication
Press releases
Recruitment complete; Empros second clinical trial
Press releases
Empros first clinical trial published
Press releases
Empros Pharma strengthen the board of directors
Press releases
Empros Pharma raises sek 40M to fully finance the upcoming proof-of-concept trial for its primary drug candidate EMP16
Press releases
Empros pharma tar in 40 msek och säkrar finansieringen av proof-of-concept-studie för EMP16
Press releases
Empros Pharma participates in Bio-Korea
Press releases
Empros CEO Arvid Söderhäll interviewed
Press releases
Pressrelease phase 2A trial
Press releases
Meet Empros in New York
Press releases
Meet Empros at Bio Europe
Press releases
Meet Empros Pharma at NLS Days
Press releases
Phase 2A trial concluded
16/05/2025
Empros Pharma Launches Pilot Trial Ahead of EMP16 Phase III Program
Read more
22/02/2024
Empros phase 2b obesity trial enrollment complete in only one month..
Read more
25/05/2023
Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16
Read more
03/05/2023
Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16
Read more
24/04/2023
Empros enters late stage clinical development of obesity treatment EMP16
Read more
20/01/2023
Empros and Megapharm announce letter of intent
Read more
06/01/2023
Securing 40 msek investment
Read more
20/09/2022
Results from phase IIA trial published in major scientific journal
Read more
02/05/2022
Annual general meeting
Read more
15/02/2021
Pharmacokinetics publication
Read more
31/08/2020
Recruitment complete; Empros second clinical trial
Read more
20/04/2020
Empros first clinical trial published
Read more
18/03/2020
Empros Pharma strengthen the board of directors
Read more
04/07/2019
Empros Pharma raises sek 40M to fully finance the upcoming proof-of-concept trial for its primary drug candidate EMP16
Read more
03/07/2019
Empros pharma tar in 40 msek och säkrar finansieringen av proof-of-concept-studie för EMP16
Read more
21/06/2018
Empros Pharma participates in Bio-Korea
Read more
19/01/2018
Empros CEO Arvid Söderhäll interviewed
Read more
11/09/2017
Pressrelease phase 2A trial
Read more
07/09/2017
Meet Empros in New York
Read more
07/09/2017
Meet Empros at Bio Europe
Read more
13/08/2017
Meet Empros Pharma at NLS Days
Read more
13/08/2017
Phase 2A trial concluded
Read more